Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach